Alain Jean Braun

USPTO Granted Patents = 12 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 77(Granted Patents)

Location History:

Boulogne Billancourt, FR (2001 - 2009)
Antony, FR (2011)
Sceaux, FR (2013)
Paris, FR (2012 - 2017)

Company Filing History:

Years Active: 2001-2017

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9675606 - 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors (2017-06-13),

2. 9126972 - 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors (2015-09-08),

3. 9120812 - Pyrimidooxazocine derivatives as mTOR-inhibitors (2015-09-01),

4. 8530657 - Substituted adamantanes and their therapeutic application (2013-09-10),

5. 8530477 - Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 (2013-09-10),

6. 8211892 - Tetrahydroquinoxaline urea derivatives (2012-07-03),

7. 7947834 - Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators (2011-05-24),

8. 7897773 - Urea derivatives of tropane, their preparation and their therapeutic application (2011-03-01),

9. 7569582 - Aminotropane derivatives, preparation thereof and therapeutic use thereof (2009-08-04),

10. 6617336 - 2-arylquinoline derivatives, preparation and therapeutic use thereof (2003-09-09),

11. 6413984 - 8-(heterocyclylmethyl)quinoline derivatives for treating urinary incontinence (2002-07-02),

12. 6331549 - 1-aminoethylquinoline derivatives for treating urinary incontinence (2001-12-18),

Title: **Alain Jean Braun: Innovator in VEGF Receptor Kinase Inhibitors**

Introduction

Alain Jean Braun is a distinguished inventor based in Sceaux, France, known for his significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 12 patents, Braun has made substantial advancements in the development of therapeutic agents targeting key biological pathways.

Latest Patents

Among his latest innovations, Braun has developed two major patents for 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives, which serve as VEGF receptor kinase inhibitors. These inventions cover the preparation process and therapeutic applications of compounds represented by a general formula (I). This groundbreaking work highlights Braun's commitment to addressing critical health challenges through innovative solutions.

Career Highlights

Braun's professional journey includes pivotal roles in renowned pharmaceutical companies, particularly Sanofi and Sanofi-Aventis. His tenure at these companies has allowed him to leverage his expertise and collaborate on various research initiatives aimed at enhancing therapeutic efficacy in the field of oncology and beyond.

Collaborations

Throughout his career, Alain Jean Braun has collaborated with notable coworkers such as Christophe Philippo and Eric Nicolai. These partnerships have fostered a creative and productive environment, further enhancing the innovative output of Braun’s research endeavors.

Conclusion

In conclusion, Alain Jean Braun's contributions to medicinal chemistry and the development of VEGF receptor kinase inhibitors underline his status as a leading inventor in the field. With a solid foundation of patents and collaboration with esteemed professionals, Braun continues to make strides in scientific research, paving the way for future innovations in therapeutic treatments.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent pending:

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com

1 patent pending (EPO):

Please report any incorrect information to support@idiyas.com